Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284382 | 0.95 | GAA (0.53) | GAAKMT2AESR1AKR1C4AKR1C3 | |
| SCHEMBL283853 | 0.95 | GAA (0.53) | GAAKMT2AESR1AKR1C4AKR1C3 | |
| SCHEMBL754404 | 0.95 | GAA (0.53) | GAAKMT2AESR1AKR1C4AKR1C3 | |
| SCHEMBL284357 | 0.95 | GAA (0.53) | GAAKMT2AESR1AKR1C4AKR1C3 | |
| Octane SCHEMBL21828749 | 0.95 | GAA (0.53) | GAAKMT2AESR1AKR1C4AKR1C3 | |
| SCHEMBL17491243 | 0.95 | GAA (0.53) | GAAKMT2AESR1AKR1C4AKR1C3 | |
| SCHEMBL13899816 | 0.95 | GAA (0.53) | GAAKMT2AESR1AKR1C4AKR1C3 | |
| SCHEMBL2050437 | 0.95 | GAA (0.53) | GAAKMT2AESR1AKR1C4AKR1C3 | |
| SCHEMBL208070 | 0.95 | GAA (0.53) | GAAKMT2AESR1AKR1C4AKR1C3 | |
| SCHEMBL283875 | 0.95 | GAA (0.53) | GAAKMT2AESR1AKR1C4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844761-B1 | Cosmetic or pharmaceutical composition comprising a condensation polymer, cosmetic treatment method employing said composition, said condensation polymer and preparation method | OREAL (FR) | 2010-05-19 | — | — | EP | claimed |
| US-20080069786-A1 | POLYCONDENSATE, COMPOSITION, TREATMENT PROCESS, AND PREPARATION PROCESS | L'OREAL (FR) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080069786-A1 | POLYCONDENSATE, COMPOSITION, TREATMENT PROCESS, AND PREPARATION PROCESS | POLR1C, PIK3C3, SUV39H2 | GAA 1891/4885KMT2A 74/4885ESR1 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.